Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Sees Large Drop in Short Interest

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) was the recipient of a significant decline in short interest in the month of October. As of October 31st, there was short interest totalling 73,800 shares, a decline of 47.8% from the October 15th total of 141,400 shares. Based on an average trading volume of 80,700 shares, the days-to-cover ratio is presently 0.9 days.

Ekso Bionics Stock Down 1.3 %

Shares of NASDAQ EKSO traded down $0.01 during trading on Thursday, reaching $0.76. The company had a trading volume of 66,851 shares, compared to its average volume of 115,384. Ekso Bionics has a 12-month low of $0.72 and a 12-month high of $3.13. The company has a quick ratio of 2.14, a current ratio of 2.81 and a debt-to-equity ratio of 0.28. The business’s 50-day moving average is $1.05 and its 200 day moving average is $1.12. The stock has a market cap of $16.70 million, a PE ratio of -1.17 and a beta of 1.47.

Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings data on Monday, October 28th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. The firm had revenue of $4.13 million during the quarter, compared to analysts’ expectations of $6.00 million. During the same quarter in the previous year, the firm earned ($0.24) earnings per share. As a group, equities analysts forecast that Ekso Bionics will post -0.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Lake Street Capital cut their target price on Ekso Bionics from $2.50 to $2.00 and set a “buy” rating on the stock in a research note on Tuesday, October 29th. HC Wainwright cut their price objective on Ekso Bionics from $10.00 to $9.00 and set a “buy” rating on the stock in a research report on Tuesday, October 29th. Finally, StockNews.com initiated coverage on Ekso Bionics in a report on Monday. They set a “hold” rating for the company.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Ekso Bionics stock. Kent Lake Capital LLC increased its stake in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 596,050 shares of the company’s stock after purchasing an additional 454,892 shares during the quarter. Kent Lake Capital LLC owned 3.28% of Ekso Bionics worth $811,000 at the end of the most recent quarter. 6.42% of the stock is currently owned by institutional investors and hedge funds.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.